- I-Mab ( NASDAQ: IMAB ) said the first patient in China had been treated with its TJ-CD4B in a Phase 1 international multi-center clinical trial for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma.
- TJ-CD4B binds to Claudin 18.2-expressing cancer cells and co-stimulatory molecule 4-1BB on T cells to exert a tumor-killing effect.
- In March, the U.S. Food and Drug Administration granted Orphan Drug Designation to TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.
For further details see:
I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China